During the past decade, Gruppo Italiano Studio Linfomi conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Gruppo Italiano Studio Linfomi" are "Chemotherapy-Induced Nausea and Vomiting" (1 trials), "Hodgkin Lymphoma" (1 trials), "Non Hodgkin's Follicular Lymphoma" (1 trials), "Non Hodgkin's Lymphoma" (1 trials) and "Relapsed or Refractory Chronic Lymphoproliferative Disorders" (1 trials). Many other conditions were trialed in "Gruppo Italiano Studio Linfomi" in a lesser frequency.

Most popular intervention types in "Gruppo Italiano Studio Linfomi" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib (VELCADE)" (1 trials), "Palonosetron" (1 trials), "Rituximab" (1 trials) and "bendamustine +/- rituximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gruppo Italiano Studio Linfomi" are 3 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Gruppo Italiano Studio Linfomi". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Gruppo Italiano Studio Linfomi, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Gruppo Italiano Studio Linfomi, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".